Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

153

Enrollment

NIH

Sponsor class

Conditions

Acute Leukemia of Ambiguous Lineage
B Acute Lymphoblastic Leukemia

Interventions

DRUG: Asparaginase Erwinia chrysanthemi
PROCEDURE: Biospecimen Collection
BIOLOGICAL: Blinatumomab
PROCEDURE: Bone Marrow Aspiration
DRUG: Calaspargase Pegol
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Daunorubicin
DRUG: Dexamethasone
DRUG: Doxorubicin
PROCEDURE: Echocardiography Test
PROCEDURE: FDG-Positron Emission Tomography
DRUG: Leucovorin
DRUG: Levoleucovorin
PROCEDURE: Lumbar Puncture
PROCEDURE: Magnetic Resonance Imaging
DRUG: Mercaptopurine
DRUG: Methotrexate
DRUG: Methylprednisolone

Sponsor

National Cancer Institute (NCI)